CV2.1 Antibody, IgG by CBA-IFA With Reflex to Titer, Serum
Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube (SST) or plain red
Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.25 mL)
Hemolyzed, contaminated, or severely lipemic specimens
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
|CV2.1 Ab IgG CBA-IFA Screen, Serum||Less than 1:10|
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
This indirect fluorescent antibody assay utilizes CV2.1 transfected cell lines for the detection and semiquantification of the CV2.1 IgG antibody.
Laboratory Developed Test (LDT)
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2013959||CV2.1 Ab IgG CBA-IFA Screen, Serum||72504-4|
- Cerebellar degeneration
- Collapsin response-mediator protein 5
- Cranial neuropathy
- Peripheral neuropathy
- Vision loss